Bio-Gene Technology Ltd. (BGT) AI Stock Analysis

• Market Cap: AU$5.06M
• Dividend Yield: N/A
• Average Volume (3M): 261.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 266,419,300
• 10 Day Avg. Volume: 339,280
• 30 Day Avg. Volume: 261,966
• PEG Ratio: -3.87
• Price to Book (P/B): 4.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: ―

Bio-Gene Technology Ltd. struggles with significant financial challenges and weak technical indicators, resulting in a low overall score. The absence of earnings and a negative P/E ratio further affect its valuation negatively. The company's debt-free balance sheet is a positive aspect but insufficient to offset the overall negative outlook.

Bio-Gene Technology Ltd. Business Overview & Revenue Model

Company Description

Bio-Gene Technology Ltd. (BGT) is an innovative biotechnology company focused on the research and development of novel pest control technologies. Operating primarily in the agricultural and public health sectors, BGT aims to provide sustainable and environmentally friendly solutions to pest management challenges. The company's core products are based on proprietary technology, which leverages natural compounds to offer alternatives to traditional chemical pesticides.

How the Company Makes Money

Bio-Gene Technology Ltd. generates revenue through the commercialization of its proprietary pest control technologies. The company's primary revenue streams include licensing agreements with agricultural and chemical companies that incorporate BGT's technology into their own product lines. Additionally, BGT engages in strategic partnerships to co-develop and distribute its products, allowing for shared revenue and expanded market reach. The company may also receive funding through grants and research collaborations aimed at advancing its technology and expanding its application areas. Sales of its own branded products, if applicable, would also contribute to its earnings.

Bio-Gene Technology Ltd. Financial Statement Overview

Summary

Bio-Gene Technology Ltd. is facing financial challenges with declining revenues, persistent losses, and negative cash flows. Despite these issues, the company benefits from a debt-free balance sheet, providing some financial stability.

Income Statement

Bio-Gene Technology Ltd. shows a declining revenue trend over the years, with a significant drop in revenue from 2023 to 2024. The company has consistently reported negative net income, indicating persistent losses. The gross profit margin is negative, reflecting challenges in covering the cost of goods sold. Additionally, negative EBIT and EBITDA margins point to inefficiencies in operations and high operating expenses relative to revenue.

Balance Sheet

The company's balance sheet reveals a strong equity position with no debt, resulting in a favorable debt-to-equity ratio of zero. The equity ratio remains high, indicating stability in financial structure. However, declining stockholders' equity and total assets over the years suggest a weakening financial position. The return on equity is negative due to the consistent net losses.

Cash Flow

Cash flow analysis shows consistent negative operating cash flows, indicating challenges in generating cash from core operations. The free cash flow has also been negative, suggesting insufficient cash flow to cover capital expenditures without external financing. The operating cash flow to net income ratio is negative, highlighting the gap between reported earnings and cash flow generation.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	-435.00	18.32K	595.08K	879.78K	573.12K	907.58K
Gross Profit	-558.91K	-301.45K	281.80K	612.64K	399.92K	640.45K
EBITDA	-2.41M	-2.97M	-3.14M	-2.92M	-2.39M	-2.05M
Net Income	-2.36M	-2.41M	-3.10M	-2.80M	-2.36M	-1.87M
Balance Sheet
Total Assets	1.87M	3.16M	3.84M	7.30M	5.00M	6.57M
Cash, Cash Equivalents and Short-Term Investments	1.34M	2.21M	2.99M	6.34M	3.93M	5.52M
Total Debt	0.00	0.00	0.00	0.00	0.00	11.66K
Total Liabilities	541.70K	368.45K	613.88K	1.03M	754.57K	567.29K
Stockholders Equity	1.33M	2.79M	3.22M	6.27M	4.25M	6.00M
Cash Flow
Free Cash Flow	-1.88M	-2.76M	-3.28M	36.67K	-1.83M	-1.64M
Operating Cash Flow	-1.88M	-2.75M	-3.28M	43.52K	-1.83M	-1.64M
Investing Cash Flow	0.00	-5.70K	0.00	-6.84K	-3.03K	0.00
Financing Cash Flow	0.00	1.98M	-75.00K	4.41M	239.88K	2.67M

Bio-Gene Technology Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BGT, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.08 is Neutral, neither overbought nor oversold. The STOCH value of 122.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BGT.

Bio-Gene Technology Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAN	73 Outperform	$1.17B	70.51	9.23%	―	10.79%	5.20%
TLX	69 Neutral	$8.19B	160.20	14.52%	―	55.85%	893.42%
CYC	49 Neutral	AU$123.92M	―	-35.20%	―	4.68%	-155.42%
Sector *	49 Neutral	AU$2.50B	4.42	-64.25%	2.77%	36.51%	13.14%
BGT	42 Neutral	AU$5.06M	―		―	―	―
IMU	40 Underperform	$93.34M	―	-99.05%	―	―	-33.99%
OPT	30 Underperform	$738.77M	―		―	-24.46%	-7.90%

Bio-Gene Technology Ltd. Corporate Events

Bio-Gene Technology Ltd Updates Securities Issue Announcement

Bio-Gene Technology Ltd announced a correction to a previous statement regarding the proposed issue of securities. This update, which addresses a typographic error, pertains to the company’s plans to offer securities under a securities purchase plan. The correction ensures clarity in the company’s communication with stakeholders and aligns with ASX listing rules, potentially impacting investor confidence and market positioning.

Bio-Gene Technology Announces Proposed Securities Issue to Boost Market Position

Bio-Gene Technology Ltd has announced a proposed issue of securities, including unlisted options and ordinary fully paid shares, as part of a securities purchase plan and placement. This move is expected to enhance the company’s financial position, potentially enabling further development of its insecticide products and strengthening its market presence.

Bio-Gene Technology Advances in Nature-Derived Insecticides

Bio-Gene Technology Ltd. presented an investor update highlighting its progress in developing nature-derived insecticides. This initiative is expected to enhance the company’s market positioning by offering sustainable solutions to pest control, potentially impacting stakeholders positively by addressing global insecticide needs.

Bio-Gene Technology Secures $2.1 Million for Key Insecticide Development

Bio-Gene Technology Ltd announced a successful capital raise of $2.1 million through a placement with sophisticated investors and plans to offer a Share Purchase Plan to eligible shareholders. The funds will be used to conduct regulatory-enabling safety studies for Flavocide®, a key step towards its approval in Australia, and to support the scale-up of Qcide, product development, and strategic projects. This financial boost is expected to significantly advance Bio-Gene’s operational capabilities and strengthen its position in the pest control industry.

Bio-Gene Technology Showcases Innovations at NWR Virtual Healthcare Conference 2025

Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference 2025, where CEO Tim Grogan will present the company’s advancements in bio-insecticides. This presentation highlights Bio-Gene’s commitment to addressing insecticide resistance and toxicity issues, potentially enhancing its market position and offering stakeholders innovative solutions for pest management.

Bio-Gene Technology to Present at NWR Virtual Healthcare Conference

Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO Tim Grogan will present on the company’s innovative insecticide solutions. This presentation highlights Bio-Gene’s commitment to addressing pest control challenges and could enhance its visibility and positioning in the bio-insecticide industry, potentially impacting stakeholders by showcasing its environmentally friendly and effective products.

Bio-Gene Technology Advances Insecticide Development and Strengthens IP Portfolio

Bio-Gene Technology Limited reported several key achievements for the six months ending December 2024, including a collaboration with Envu to develop Flavocide® for mosquito management, successful pilot-scale production of Flavocide, and the initiation of safety studies in Europe and India. The company also completed its thirteenth Qcide® harvest, improved seed and seedling production, and expanded formulation development programs. Additionally, Bio-Gene strengthened its intellectual property portfolio with six new patents and five new applications, positioning itself strongly in the bio-insecticide market.